Endokrynologia Polska · 2019 · 15 citations · 6 references
MedicineEndocrinologyPediatricsHuman NutritionPediatric EndocrinologyPediatric TherapeuticsChild GrowthGrowth DisordersGrowth Factor TherapyGrowth HormoneGrowth Hormone TherapyPediatric GrowthGrowth Outcomes In ChildrenGrowth Velocity AssessmentInsulin-like Growth Factor 1 DeficiencyInsulin-like Growth Factor DeficiencyInsulin-like Growth Factor-1Insulin-like Growth FactorsPre-treatmentSerious Adverse Events
INTRODUCTION: The objective of this study was to analyse the effects of the first three years of treatment with recombinant human insulinlike growth factor 1 (rhIGF-1) in patients from the Polish population. MATERIAL AND METHODS: Twenty-seven children (22 boys and five girls) aged 2.8 to 16.0 years old were qualified for treatment with rhIGF-1 (mecasermin) in different treatment centres, according to Polish criteria: body height below -3.0 SD and IGF-1 concentration below percentile 2.5 with normal growth hormone (GH) levels. Mecasermin initial dose was 40 μg/kg bw twice a day and was subsequently increased to an average of 100 μg/kg bw twice a day. Body height, height velocity, weight, body mass index (BMI), and adverse events were measured. RESULTS: Mecasermin treatment resulted in a statistically significant increase in body height (1.45 ± 1.06 SD; p < 0.01) and height velocity in comparison with pre-treatment values. The biggest change in height velocity happened during the first year and diminished during subsequent years. Body weight and BMI also increased significantly after treatment (1.16 ± 0.76 SD and 0.86 ± 0.75 SD, respectively; p < 0.01). Eight patients reported adverse events. These were mild and temporary and did not require treatment modification except in two patients. CONCLUSIONS: Treatment with rhIGF-1 was effective and safe in Polish patients with primary IGF-1 deficiency. It had a clear beneficial effect on the height of the patients and significantly accelerated the height velocity, particularly in the first year of treatment.
6
Steven D. Chernausek, Philippe Backeljauw, James W. Frane et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 246 citations · Full text
Medicine, Endocrinology, Pediatrics +16
Jaime Guevara‐Aguirre, Arlan L. Rosenbloom, Oswaldo Vasconez et al. · The Journal of Clinical Endocrinology & Metabolism · 1997 · 121 citations · Full text
Medicine, Endocrinology, Pediatrics +17
Long-Term Treatment of Growth Hormone Insensitivity Syndrome with IGF-I
Michael B. Ranke, M O Savage, Pierre Chatelain et al. · Hormone Research in Paediatrics · 1999 · 117 citations
L. Kurt Midyett, Alan D. Rogol, Quentin L. Van Meter et al. · The Journal of Clinical Endocrinology & Metabolism · 2009 · 72 citations · Full text
Medicine, Endocrinology, Pediatrics +17